TRANSCRIPTION FACTORS AS THERAPEUTIC TARGETS IN FOCAL SEGMENTAL GLOMERULAR SCLEROSIS

$2,455,660FY2022Department of the ArmyDOD

Beth Israel Deaconess Medical Center, Inc.

Investigators